Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis.

IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY BMC Nephrology Pub Date : 2024-10-01 DOI:10.1186/s12882-024-03784-8
Ayşe Serra Artan, Şafak Mirioğlu, Rabia Hacer Hocaoğlu, Kenan Turgutalp, Saide Elif Güllülü Boz, Necmi Eren, Mevlüt Tamer Dinçer, Sami Uzun, Gülizar Şahin, Sim Kutlay, Şimal Köksal Cevher, Hamad Dheir, Mürvet Yılmaz, Taner Baştürk, Erhan Tatar, İlhan Kurultak, Ramazan Öztürk, Hakkı Arıkan, Serap Yadigar, Onur Tunca, Kültigin Türkmen, Ömer Celal Elçioğlu, Bülent Kaya, Şebnem Karakan, Yavuz Ayar, Cuma Bülent Gül, Halil Yazıcı, Savaş Öztürk
{"title":"Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis.","authors":"Ayşe Serra Artan, Şafak Mirioğlu, Rabia Hacer Hocaoğlu, Kenan Turgutalp, Saide Elif Güllülü Boz, Necmi Eren, Mevlüt Tamer Dinçer, Sami Uzun, Gülizar Şahin, Sim Kutlay, Şimal Köksal Cevher, Hamad Dheir, Mürvet Yılmaz, Taner Baştürk, Erhan Tatar, İlhan Kurultak, Ramazan Öztürk, Hakkı Arıkan, Serap Yadigar, Onur Tunca, Kültigin Türkmen, Ömer Celal Elçioğlu, Bülent Kaya, Şebnem Karakan, Yavuz Ayar, Cuma Bülent Gül, Halil Yazıcı, Savaş Öztürk","doi":"10.1186/s12882-024-03784-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort.</p><p><strong>Methods: </strong>In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death.</p><p><strong>Results: </strong>Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036).</p><p><strong>Conclusions: </strong>Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12882-024-03784-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort.

Methods: In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death.

Results: Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036).

Conclusions: Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
原发性膜性肾病的免疫抑制治疗模式和疗效观察研究:多中心回顾性分析。
背景我们在一个大型全国队列中评估了不同免疫抑制方案对原发性膜性肾病患者的疗效:在这项登记研究中,纳入了来自 47 个中心的 558 名患者,这些患者至少接受过一种免疫抑制剂治疗,并有足够的随访数据。主要结果定义为完全缓解(CR)或部分缓解(PR)。次要综合结果是估计肾小球滤过率(eGFR)至少下降 50%、开始肾脏替代疗法、发展为慢性肾脏病 5 期或死亡:确诊时的中位年龄为 48 岁(IQR:37-57),358 人(64.2%)为男性。患者的随访时间中位数为 24 个月(IQR:12-60 个月)。钙神经蛋白抑制剂(CNIs)联合或不联合糖皮质激素是最常用的治疗方案(43.4%),其次是糖皮质激素和环磷酰胺(GC-CYC)(39.6%)、糖皮质激素单药治疗(25.8%)和利妥昔单抗(RTX)(9.1%)。总体缓解率为 66.1%(CR 26.7%,PR 39.4%),59 例(10.6%)患者达到了次要综合结果。多变量逻辑回归显示,基线 eGFR(OR 1.011,95% CI:1.003-1.019,P = 0.007)、血清白蛋白(OR 1.682,95% CI:1.269-2.231,P 结论:基线 eGFR 和血清白蛋白越高,缓解率越高:基线 eGFR 和血清白蛋白水平越高,缓解率越高。接受 RTX 治疗的患者缓解率较低,而接受 GC-CYC 治疗的患者缓解率较高。由于该研究具有回顾性,而且采用了多种治疗方法,因此在解释这些发现时需要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Nephrology
BMC Nephrology UROLOGY & NEPHROLOGY-
CiteScore
4.30
自引率
0.00%
发文量
375
审稿时长
3-8 weeks
期刊介绍: BMC Nephrology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
期刊最新文献
Centre-level fluid management practices in the BISTRO trial and their lack of association with participant fluid status and blood pressure in non-anuric haemodialysis patients. Impact of COVID-19 on nephropathy in diabetes mellitus type-II patients: a systematic literature review and meta-analysis. Association between different proportions of crescents and the progression of IgA nephropathy (IgAN): a systematic review and meta-analysis. Decoy cells detected in the urine of a patient with complex karyotype Myelodysplastic neoplasms who underwent umbilical cord blood transplantation: a case report. Internal hernia following laparoendoscopic single site surgery: a case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1